Zimmer Biomet has adjusted its 2025 earnings forecast to $7.90-$8.10 per share, down from previous estimates falling between $8.15-$8.35, due to the Trump administration’s tariffs. The orthopaedic giant’s stock fell by almost 12% after revealing on 5 May that tariffs would contribute to a $60m-$80m drag on its operating profit in 2025. Zimmer elaborated on the revised projections in its Q1 2025 earnings call. During the quarter, the company achieved around $1.9bn in net sales, indicative of a 1.1% increase on a constant currency basis. Zimmer’s chief financial officer and finance, operations and supply chain EVP Suketu Upadhyay noted that while the tariff situation “remains fluid”, the company anticipates an impact of a “$60m to $80m” headwind to operating profit in 2025, with the “majority” of the impact falling in the second half of the year. Upadhyay said: “This estimate contemplates our latest view of mitigation efforts currently underway and that the announced European reciprocal tariffs will go into effect after the 90-day stay period.” Along with Zimmer’s recent $1.2bn acquisition of Paragon 28 earlier this year, due to tariffs, the company anticipates its full-year operating margins to be down by 100 to 150 basis points versus 2024. Upadhyay added: “I will note that our 2025 impact should not be used as a run rate for 2026 due to a variety of factors, and that our estimate around the impact of tariffs in 2025 could change as the macro environment continues to unfold.” While noting that the majority of its manufacturing is undertaken within the US, Zimmer also has manufacturing sites in the Chinese cities of Jintan and Zhejiang. Trump’s tariffs have heavily targeted China, with levies rising since the nation imposed 34% tariffs in response to those Trump announced would come into force on Chinese imports on 9 April. While the president has since stated that levies for goods imported from the country will “come down substantially” yet “won’t be zero”, they remain at 145% for now. To mitigate some of the tariff impact, Upadhyay also shared that Zimmer is optimising “in our view of country of origin”, potentially alluding to a diminishment in its China-based manufacturing activities. Other players in the medtech space are attempting to factor in the impact the Trump administration’s current tariff measures may have on their bottom line in 2025. Anticipating that its 2025 revenues may take a hit of around $500m, imaging giant GE HealthCare has downshifted its earnings per share profit to fall within the $3.90-$4.10 per share range, down from previous guidance between $4.61 and $4.75 per share. Story Continues While Stryker’s recent Q1 2025 performance beat market estimates by a wafer-thin $0.13 margin, the medical device company is also slimming its 2025 outlook. Anticipating a tariff revenue impact of around $200m for 2025, Stryker recently pruned its year-end guidance to $13.20 to $13.45 versus previous adjusted net earnings per diluted share estimates in the $13.45-$13.70 range. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData’s Strategic Intelligence here. "Zimmer Biomet flags $60m-$80m tariff impact on 2025 profits" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments
Zimmer Biomet flags $60m-$80m tariff impact on 2025 profits
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...